Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P38646: Variant p.Thr539Lys

Stress-70 protein, mitochondrial
Gene: HSPA9
Feedback?
Variant information Variant position: help 539 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Threonine (T) to Lysine (K) at position 539 (T539K, p.Thr539Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (T) to large size and basic (K) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page



Sequence information Variant position: help 539 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 679 The length of the canonical sequence.
Location on the sequence: help EVTFDIDANGIVHVSAKDKG T GREQQIVIQSSGGLSKDDIE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         EVTFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDDIE

                              KLPFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDDIE

Mouse                         EVTFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDDIE

Rat                           EVTFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDDIE

Bovine                        EVTFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDDIE

Chicken                       EVTFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDEIE

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 47 – 679 Stress-70 protein, mitochondrial
Region 432 – 679 Interaction with FXN and ISCU
Mutagenesis 555 – 555 K -> A. Reduces interaction with UBXN2A.
Mutagenesis 558 – 558 I -> A. Abolishes interaction with UBXN2A.
Turn 537 – 539



Literature citations
Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9.
Schmitz-Abe K.; Ciesielski S.J.; Schmidt P.J.; Campagna D.R.; Rahimov F.; Schilke B.A.; Cuijpers M.; Rieneck K.; Lausen B.; Linenberger M.L.; Sendamarai A.K.; Guo C.; Hofmann I.; Newburger P.E.; Matthews D.; Shimamura A.; Snijders P.J.; Towne M.C.; Niemeyer C.M.; Watson H.G.; Dziegiel M.H.; Heeney M.M.; May A.; Bottomley S.S.; Swinkels D.W.; Markianos K.; Craig E.A.; Fleming M.D.;
Blood 126:2734-2738(2015)
Cited for: INVOLVEMENT IN SIDBA4; VARIANTS SIDBA4 PRO-212; SER-388; LYS-415 AND 458-ILE-ASN-459 DEL; VARIANTS LEU-200; LYS-539; TRP-573 AND LYS-577;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.